Brokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) PT at $6.25
TNYA has been the subject of several recent research reports. Chardan Capital decreased their price objective on Tenaya Therapeutics from $18.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, March 12th. Morgan Stanley reduced their price target on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Tenaya Therapeutics in a research note on Friday. Finally, Canaccord Genuity Group reduced their price objective on shares of Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, March 13th.
In other Tenaya Therapeutics news, major shareholder Group Gp Lp Column III purchased 35,714,284 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was bought at an average cost of $0.70 per share, for a total transaction of $24,999,998.80. Following the completion of the purchase, the insider now owns 49,313,559 shares in the company, valued at $34,519,491.30. This represents a 262.62 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 19,621 shares of company stock worth $10,595 in the last 90 days. 32.76% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the stock. Synovus Financial Corp acquired a new position in Tenaya Therapeutics during the 3rd quarter valued at approximately $28,000. Woodline Partners LP acquired a new position in shares of Tenaya Therapeutics in the 4th quarter valued at $28,000. Commerce Bank purchased a new position in Tenaya Therapeutics in the 4th quarter worth $29,000. Mariner LLC purchased a new stake in Tenaya Therapeutics during the 4th quarter valued at about $30,000. Finally, Ground Swell Capital LLC acquired a new position in shares of Tenaya Therapeutics in the fourth quarter valued at about $32,000. 90.54% of the stock is currently owned by institutional investors and hedge funds.
Shares of TNYA stock opened at $0.49 on Wednesday. The company has a market capitalization of $43.02 million, a P/E ratio of -0.34 and a beta of 2.98. The company’s 50-day simple moving average is $0.63 and its two-hundred day simple moving average is $1.46. Tenaya Therapeutics has a one year low of $0.39 and a one year high of $4.96.
Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) last released its quarterly earnings data on Monday, March 17th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. On average, research analysts expect that Tenaya Therapeutics will post -1.35 EPS for the current fiscal year.
Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.
- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
